Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.
Actively Recruiting
Evaluating 18FPSMA-1007 PETCT Imaging Accuracy in Newly Diagnosed High-Risk Prostate Cancer Patients
Researchers are evaluating the diagnostic accuracy of 18FPSMA-1007 PETCT imaging in men newly diagnosed with high-risk or very-high-risk prostate cancer. This phase 3 study focuses on patients with biopsy-confirmed, clinically localized prostate adenocarcinoma who are candidates for curative prostatectomy with extended pelvic lymph node dissection. The goal is to compare PETCT results with tissue histology to assess how well this imaging detects pelvic nodal disease. Participants will receive a single intravenous dose of 18FPSMA-1007, a diagnostic radiopharmaceutical, followed by a PET scan. Prior to this, they must have completed conventional imaging methods like CT or MRI and, if needed, a bone scan. This study includes only one group undergoing this imaging procedure to evaluate its diagnostic performance. During the study, participants will undergo PETCT imaging, and results will be compared with histology obtained 6 to 8 weeks after surgery to measure sensitivity and specificity. Researchers will monitor eligibility, adverse reactions, and adherence to the imaging protocol. The total participation duration extends until after surgery and histological analysis, with the primary outcome measured several weeks post-surgery.
Actively Recruiting
Researchers are conducting a multicenter, randomized controlled trial to evaluate the effect of applying the polysaccharide agent ARISTA13 AH during robotic-assisted radical prostatectomy RARP for prostate cancer. The study aims to determine if this agent reduces postoperative blood loss by measuring hemoglobin levels after surgery. Additionally, the trial explores the impact on erectile function using the IIEF-5 score at 3, 6, and 12 months post-surgery. Participants will be randomly assigned to one of two groups one group will receive a 5g application of ARISTA13 AH to the prostate bed and neurovascular bundles during and at the end of surgery to control bleeding, while the other group will not receive this agent in these areas. No other hemostatic agents will be used in the treated areas. The surgery involves nerve-sparing techniques either unilaterally or bilaterally. Throughout the study, participants will be monitored for changes in hemoglobin levels from before surgery to 5-6 days afterward, as well as their erectile function at specified time points up to one year. Safety evaluations include monitoring for surgical complications and the integrity of the anastomosis. The total duration of participation includes the surgery and follow-up visits up to 12 months after RARP.